Iwona Lugowska
Overview
Explore the profile of Iwona Lugowska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
1122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oaknin A, Lee J, Makker V, Oh D, Banerjee S, Gonzalez-Martin A, et al.
Adv Ther
. 2025 Mar;
PMID: 40048102
of the original article, 'Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02'. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate, which...
2.
Weichenthal M, Mangana J, Gavrilova I, Lugowska I, Shalamanova G, Kandolf L, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39517999
Background: Although data on patients treated with pembrolizumab are available from clinical trials and single-country real-world reports, to our knowledge no multi-country real-world studies have investigated the use of pembrolizumab...
3.
Verlingue L, Italiano A, Prenen H, Alia E, Tosi D, Perets R, et al.
EBioMedicine
. 2024 Oct;
109:105374.
PMID: 39395231
Background: Simlukafusp alfa (FAP-IL2v) is an immune cytokine engineered to selectively promote immune responses in the tumour microenvironment. We evaluated the antitumour activity and safety of FAP-IL2v plus atezolizumab in...
4.
Oaknin A, Lee J, Makker V, Oh D, Banerjee S, Gonzalez-Martin A, et al.
Adv Ther
. 2024 Sep;
41(11):4125-4139.
PMID: 39261417
Introduction: DESTINY-PanTumor02 (NCT04482309) evaluated the efficacy and safety of trastuzumab deruxtecan (T-DXd) in pretreated patients with human epidermal growth factor receptor 2 (HER2)-expressing [immunohistochemistry (IHC) 3+/2+] solid tumors across seven...
5.
Shapira-Frommer R, Niu J, Perets R, Peters S, Shouse G, Lugowska I, et al.
Future Oncol
. 2024 Sep;
20(27):1983-1991.
PMID: 39230120
Vibostolimab, a humanized IgG1 monoclonal antibody, blocks the interaction between TIGIT and its ligands, preventing the immunosuppressive effects of TIGIT. The addition of vibostolimab to the PD-1 inhibitor pembrolizumab has...
6.
Frezza A, Leonard H, Aggerholm-Pedersen N, Badalamenti G, Baili P, Baldi G, et al.
PLoS One
. 2024 Aug;
19(8):e0308387.
PMID: 39133752
Introduction: Epithelioid hemangioendothelioma (EHE) is an ultra-rare sarcoma, marked by distinctive molecular and pathological features and with a variable clinical behavior. Its natural history is still partially understood, reliable prognostic...
7.
Kulecka M, Czarnowski P, Balabas A, Turkot M, Kruczkowska-Tarantowicz K, Zeber-Lubecka N, et al.
Int J Mol Sci
. 2024 Aug;
25(15).
PMID: 39125593
The key association between gut dysbiosis and cancer is already known. Here, we used whole-genome shotgun sequencing (WGS) and gas chromatography/mass spectrometry (GC/MS) to conduct metagenomic and metabolomic analyses to...
8.
Platkowska A, Slowinska M, Zalewska J, Swacha Z, Szumera-Cieckiewicz A, Wagrodzki M, et al.
J Clin Med
. 2024 Aug;
13(15).
PMID: 39124644
: Non-melanocytic benign skin tumours encompass a diverse group of lesions, classified based on their cellular origin, such as epidermal, vascular, fibrous, neural, muscle, and adnexal tumours. Though they often...
9.
Schenker M, Burotto M, Richardet M, Ciuleanu T, Goncalves A, Steeghs N, et al.
J Immunother Cancer
. 2024 Aug;
12(8).
PMID: 39107131
Background: Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies. This study evaluated the efficacy...
10.
Horgan D, Hofman P, Buttner R, Riess O, Lugowska I, Dube F, et al.
Diagnosis (Berl)
. 2024 Aug;
12(1):94-107.
PMID: 39088796
Objectives: This paper aims to identify and address gaps in cancer treatment and diagnosis within European health services, focusing specifically on discrepancies between clinical guidelines and policy guidelines. It seeks...